Molecular-guided therapy improves survival in unfavorable cancer of unknown primary
1. Patients in the MGT group reported a significantly greater progression-free survival than those in the standard platinum-based chemotherapy group. ...
Tag: chemotherapy
#VisualAbstract: Three Cycles of Chemotherapy was Noninfererior to Six Cycles for High-Risk Retinoblastoma
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors
1. Treatment of desmoid tumours with dual anti-CTLA-4 and anti-PD-1 blockade with ipilimumab and nivolumab resulted in an overall response ...
Datopotamab deruxtecan may be a novel improvement for inoperable breast cancer
1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug ...
#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract Molecular Guided Therapy Improves Survival for Unfavourable Cancer of Unknown Origin
Click here to read this study in Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
#VisualAbstract: Atezolizumab and Chemotherapy Improve Outcomes in Advanced or Recurrent Endometrial Cancer
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Blinatumomab Improves Survival in MRD-Negative Acute Lymphoblastic Leukemia in Adults
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Sintilimab improves survival in advanced non-metastatic nasopharyngeal carcinoma
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36 months compared to the standard therapy ...